Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803 With or Without bNAbs for HIV-1 Control During Analytic Treatment Interruption
NCT04340596Phase 1Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2021
- Primary completion
- May 2026
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nogapendekin alfa inbakicept in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of a Grade >=3 adverse event (AE) that is at least possibly related to N-803, Number of N-803 doses completed and 2 more. Started May 2021; status: active, not recruiting.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04340596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340596.